MyoStrain® Implemented at Ramón y Cajal Hospital, The First of Six Large Madrid Hospitals

MORRISVILLE, N.C., November 15, 2022 – Myocardial Solutions, Inc. (MSI) has just launched MyoStrain® in the first of six hospitals in Madrid, Spain as part of our innovation initiative.

Ramón y Cajal University Hospital in the Community of Madrid is the first to begin implementing MyoStrain® innovative cardiac software. The hospital acquired MyoStrain® to assess the cardiac function of 1,000 patients, primarily focusing on the new European Society of Cardiology(ESC) guidelines for Cardio-Oncology. In addition, MyoStrain® testing will be performed on cardiology patients in need of cardiac function assessment as well as patients battling HIV and other infectious diseases including long COVID. MyoStrain® allows the evaluation of cardiac dysfunction in a fast, accurate, reproducible and non-invasive way. Early detection is critical to cardiac health outcomes since initial dysfunction is often asymptomatic.

Ramón y Cajal University Hospital in the Community of Madrid is the first to begin implementing MyoStrain® innovative cardiac software. The hospital acquired MyoStrain® to assess the cardiac function of1,000 patients, primarily focusing on the new European Society of Cardiology (ESC) guidelines for Cardio-Oncology. In addition, MyoStrain® testing will be performed on cardiology patients in need of cardiac function assessment as well as patients battling HIV and other infectious diseases including long COVID. MyoStrain® allows the evaluation of cardiac dysfunction in a fast, accurate, reproducible and non-invasive way. Early detection is critical to cardiac health outcomes since initial dysfunction is often asymptomatic.

Madrid Community Minister of Health, Enrique Ruiz Escudero, delivered remarks at Ramón y Cajal Hospital’s public presentation of MyoStrain® on Friday. Ruiz Escudero said, "Ramón y Cajal is the first public hospital in Spain and one of the first in Europe to have 'MyoStrain,' an innovative advance that allows non-invasive evaluation of the patient's cardiac function.” Ruiz Escudero emphasized that MyoStrain®, "facilitates the detection of early dysfunction, i.e., we can consider it as a preventive tool for early pathology that cannot be detected by current conventional diagnostic methods.”

Ruiz Escudero continued by stating, “MyoStrain innovative technology can be used with to early detect cardiotoxicity in cancer patients for optimal cardio protection as well as to address the many cancer survivors, to control possible damage as a result of the treatment. These two aspects of the technology were included in the recommendations of the European guidelines on cardiotoxicity this past August.” Ruiz Escudero concluded that "It is a test that anticipates the disease, treats patients early and in a personalized way, and avoids possible complications, improving their quality of life. All this is performed without ionizing radiation or intravenous contrast.”

According to Dr. Javier Blázquez, head of Imaging Services at Ramón y Cajal University Hospital, “MyoStrain® technology will open an exciting and more personalized new world of cardiac prevention.”  In his speech at the event, he emphasized that the hospital is the first public center in Spain to use MyoStrain® technology. Dr. Blázquez also spoke of the hospital’s known reputation across Spain and Europe as a pioneer in incorporating innovation and state-of-the-art diagnostic imaging technology, including the most advanced image analysis and processing tools to improve efficiency, overall healthcare and patients’ lives in Madrid.

‍

‍